Discover and read the best of Twitter Threads about #RenalCellCancer
Most recents (2)
@TumorBoardTues 1/15 #TumorBoardTuesday #RenalCellCancer #OncTwitter
63 👩🏻 with 1 month hematuria
h/o HTN
Inflammatory Bowel Disease #IBD
Type 2 DM
🩻CT scan: 7 cm hyper enhancing L renal mass; no enlarged LN; no other distant abnormalities
✂️Patient undergoes L radical nephrectomy
63 👩🏻 with 1 month hematuria
h/o HTN
Inflammatory Bowel Disease #IBD
Type 2 DM
🩻CT scan: 7 cm hyper enhancing L renal mass; no enlarged LN; no other distant abnormalities
✂️Patient undergoes L radical nephrectomy
@TumorBoardTues @CParkMD @declangmurphy @TiansterZhang @Uromigos @montypal @DrChoueiri @AlbigesL @neerajaiims 2/15 #TumorBoardTuesday #RenalCellCancer #OncTwitter
🔬: clear cell RCC, grade 2, pT3aNx (perinephric fat invasion), no sarcomatoid features
👩🏻uneventful recovery
📆F/u 6 weeks
🩻CT c/a/p NED 🎉
🔮Pt asks about future needs
🤨What would you offer patient next?
🔬: clear cell RCC, grade 2, pT3aNx (perinephric fat invasion), no sarcomatoid features
👩🏻uneventful recovery
📆F/u 6 weeks
🩻CT c/a/p NED 🎉
🔮Pt asks about future needs
🤨What would you offer patient next?
@TumorBoardTues @CParkMD @declangmurphy @TiansterZhang @Uromigos @montypal @DrChoueiri @AlbigesL @neerajaiims 3/15 #TumorBoardTuesday
👨🏻🏫Mini tweetorial 1
✨Risk of recurrence of resected renal cancer✨
📍Tumor stage
📍grade
📍presence of necrosis or sarcomatoid features
📍performance status
📍symptoms on presentation
Patient would have ≈ 30% risk of recurrence at 5yrs.
👨🏻🏫Mini tweetorial 1
✨Risk of recurrence of resected renal cancer✨
📍Tumor stage
📍grade
📍presence of necrosis or sarcomatoid features
📍performance status
📍symptoms on presentation
Patient would have ≈ 30% risk of recurrence at 5yrs.
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 2/5 #TumorBoardTuesday
Thurs Case🎀
Take🏠messages
✅BRCAm= 10-20% of TNBC!
✅PD-L1 CPS>10= PFS & OS benefit w/ IO in mTNBC
✅PARPi= PFS benefit
✅Biomarkers, side effects, pt pref key
📚We captured much of @dradityabardia @ariellemedford’s discussion: twitter.com/i/events/15548…
Thurs Case🎀
Take🏠messages
✅BRCAm= 10-20% of TNBC!
✅PD-L1 CPS>10= PFS & OS benefit w/ IO in mTNBC
✅PARPi= PFS benefit
✅Biomarkers, side effects, pt pref key
📚We captured much of @dradityabardia @ariellemedford’s discussion: twitter.com/i/events/15548…
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD 3/5 #TumorBoardTuesday
Thursday Case🎀
How do you choose IO vs PARPi in #TNBC w #BRCA mutation? Check out the summary and algorithm below!
Important to know there are more 2L options as well, including sacituzumab-gov & other ADCs. New trials evaluating IO+ PARPi–stay tuned!
Thursday Case🎀
How do you choose IO vs PARPi in #TNBC w #BRCA mutation? Check out the summary and algorithm below!
Important to know there are more 2L options as well, including sacituzumab-gov & other ADCs. New trials evaluating IO+ PARPi–stay tuned!
@TumorBoardTues @dradityabardia @ArielleMedford @Latinamd @EricaMarieRomn1 @HillStirSci @ErikaHamilton9 @stolaney1 @PTarantinoMD @DFCI_BreastOnc @oreganruth @marina_sharifi @JaniceTNBCmets @OncBrothers @Myshastry @BRCAUmbrella 4/5 #TumorBoardTuesday
Remember #TumorBoardTuesday offers AMA & now MOC credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/tbteval
ALL CME 🔗: integrityce.com/tbt
Remember #TumorBoardTuesday offers AMA & now MOC credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/tbteval
ALL CME 🔗: integrityce.com/tbt
